Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 5 New Entrants companies in Carbonic anhydrase inhibitor
by Most Patent Filing In 3 Years in the United States in 2019

The Carbonic anhydrase inhibitor top 5 is Discovery PatSnap’ annual ranking of the top 5 Most Patent Filing In 3 Years Carbonic anhydrase inhibitor New Entrants in the United States. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2019, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Carbonic anhydrase inhibitors are a class of pharmaceuticals that suppress the activity of carbonic anhydrase. Their clinical use has been established as anti-glaucoma agents, diuretics, antiepileptics, in the management of mountain sickness, gastric and duodenal ulcers, idiopathic intracranial hypertension, neurological disorders, or osteoporosis.
#
Company Name
Region
Tech Topics
Total
Page generation time: Apr 29 2025